Exchange: NASDAQ·Updated 07:19 PM EDT
DYN logo

DYNDyne Therapeutics Inc

$23.07
$1.28
(5.87%)
Today
Closed $23.07
$0.0901
(0.39%)
After Hours
EarningsJul 27
Mkt Cap$3.81B
Vol2.16M
News
all
press releases
Dyne Therapeutics vs. Vertex Pharmaceuticals: Which Drug Innovator Stock Is a Better Buy in 2026?
Key PointsDyne Therapeutics focuses on high-potential therapies for rare neuromuscular diseases using its proprietary FORCE platform...
Nasdaq News: Markets
News Placeholder
More News
News Placeholder
Dyne Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Key PointsDyne Therapeutics is leveraging its FORCE platform to target rare neuromuscular diseases with high unmet need...
Nasdaq News: Markets
News Placeholder
Dyne Therapeutics (DYN) Reaches Key Regulatory Milestone
Dyne Therapeutics (DYN) Reaches Key Regulatory Milestone...
Yahoo! Finance: News
News Placeholder
Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean
Key PointsFCPM III sold 818,460 shares of Dyne Therapeutics last quarter; the estimated transaction value was $14.11 million based on average prices...
Nasdaq News: Markets
News Placeholder
Dyne Therapeutics Stock Gains 4.5% After BLA Filing for DMD Therapy
DYN shares jump after the company files a BLA with the FDA for z-rostudirsen in Duchenne muscular dystrophy.
Zacks
News Placeholder
Dyne Stock Gains 10% on Initiation of Late-Stage Study in DMD Patients
DYN shares jump 10% after launching a phase III study of z-rostudirsen in Duchenne muscular dystrophy patients amenable to exon 51 skipping.
Zacks
News Placeholder
DYN Stock Gains As It Gears Up For Accelerated Approval Of DMD Therapy: Wall Street Sees 140% Upside
Dyne said it plans to submit an application seeking accelerated approval of z-rostudirsen to the U.S. Food and Drug Administration later this quarter.
Stocktwits
News Placeholder
Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares
Key PointsSaturn V sold 822,007 shares of Dyne Therapeutics in the first quarter; the estimated transaction value was $14.17 million based on quarterly average prices...
Nasdaq News: Markets
News Placeholder
Dyne Therapeutics (DYN) Upgraded to Buy: Here's What You Should Know
Dyne Therapeutics (DYN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks
News Placeholder
Dyne Therapeutics Q1 Net Loss Widens
(RTTNews) - Dyne Therapeutics, Inc. (DYN) reported Monday that net loss for the first quarter was $120.85 million or $0.73 per share, compared to net loss of $115.36 million or $1.05 per share in the prior-year quarter...
Nasdaq News: Markets
<
1
2
...
>

Advertisement|Remove ads.